Lihor A. Simkevitz
Plus aucun poste en cours
Profil
Lihor A.
Simkevitz worked as a Partner at Rose International, Inc. and as a Research Associate at Scotia Capital, Inc. and ProMIS Neurosciences, Inc. before becoming a Principal at Affinium Pharmaceuticals Ltd.
Simkevitz holds an MBA from Rotman School of Management and a graduate degree from the University of Toronto.
Anciens postes connus de Lihor A. Simkevitz
| Sociétés | Poste | Fin |
|---|---|---|
Scotia Capital, Inc. (Broker)
 Scotia Capital, Inc. (Broker) Investment Banks/BrokersFinance Scotia Capital, Inc. (Broker) (Scotia Capital-Broker) is the broker-dealer division of Scotia Capital, Inc., a full-service financial services firm headquartered in Toronto, Canada. The firm is owned by The Bank of Nova Scotia (NYSE, TSE: BNS). Scotia Capital-Broker delivers a broad range of electronic trading products such as high-touch, low-latency, market access and a broad algorithmic trading suite for a wide range of clients globally. They publish monthly indexes to help investors track the performance of Canadian Hedge Funds and Alternative Mutual Funds. | Analyst-Equity | - |
Rose International, Inc. (Missouri)
 Rose International, Inc. (Missouri) Information Technology ServicesTechnology Services Rose International, Inc. provides information technology, consulting and outsourcing services. It specializes in staffing, application development, employment outsourcing services, enterprise workforce group, call center, database performance optimization, project management. The company was founded by Himanshu Bhatia and Gulab Bhatia in 1993 and is headquartered in Chesterfield, MO. | Corporate Officer/Principal | 30/04/2009 |
| PROMIS NEUROSCIENCES, INC. | Corporate Officer/Principal | 30/06/2007 |
Affinium Pharmaceuticals Ltd.
 Affinium Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Affinium Pharmaceuticals Ltd. is a holding company, which engages in the provision of clinical development of antibacterial. It specializes in hte development of antibiotics that targets the bacterial fatty acid synthesis pathway. It focuses on small molecule antibacterials targeting FabI, an essential enzyme in the bacterial fatty acid cycle. The company was founded in 2000 and is headquartered in Austin, TX. | Corporate Officer/Principal | 30/03/2006 |
Formation de Lihor A. Simkevitz
| Rotman School of Management | Masters Business Admin |
| University of Toronto | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| PROMIS NEUROSCIENCES, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Rose International, Inc. (Missouri)
Rose International, Inc. (Missouri) Information Technology ServicesTechnology Services Rose International, Inc. provides information technology, consulting and outsourcing services. It specializes in staffing, application development, employment outsourcing services, enterprise workforce group, call center, database performance optimization, project management. The company was founded by Himanshu Bhatia and Gulab Bhatia in 1993 and is headquartered in Chesterfield, MO. | Technology Services |
Scotia Capital, Inc. (Broker)
Scotia Capital, Inc. (Broker) Investment Banks/BrokersFinance Scotia Capital, Inc. (Broker) (Scotia Capital-Broker) is the broker-dealer division of Scotia Capital, Inc., a full-service financial services firm headquartered in Toronto, Canada. The firm is owned by The Bank of Nova Scotia (NYSE, TSE: BNS). Scotia Capital-Broker delivers a broad range of electronic trading products such as high-touch, low-latency, market access and a broad algorithmic trading suite for a wide range of clients globally. They publish monthly indexes to help investors track the performance of Canadian Hedge Funds and Alternative Mutual Funds. | Finance |
Affinium Pharmaceuticals Ltd.
Affinium Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Affinium Pharmaceuticals Ltd. is a holding company, which engages in the provision of clinical development of antibacterial. It specializes in hte development of antibiotics that targets the bacterial fatty acid synthesis pathway. It focuses on small molecule antibacterials targeting FabI, an essential enzyme in the bacterial fatty acid cycle. The company was founded in 2000 and is headquartered in Austin, TX. | Health Technology |
